Quick Answer
ATOSSA THERAPEUTICS, INC. reported Operating Income Loss of -$37.14 million for the year ending 2025.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -34.5% in Operating Income Loss from 2024 to 2025.
- This data is from ATOSSA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ATOSSA THERAPEUTICS, INC.'s Operating Income Loss has declined by 983.1%.
- Historical annual values: Fiscal year 2025: -$37.14 million | Fiscal year 2024: -$27.62 million | Fiscal year 2023: -$31.38 million | Fiscal year 2022: -$27.69 million | Fiscal year 2021: -$20.52 million | Fiscal year 2020: -$14.61 million | Fiscal year 2019: -$17.27 million | Fiscal year 2018: -$11.43 million | Fiscal year 2017: -$7.65 million | Fiscal year 2016: -$7.97 million | Fiscal year 2015: -$12.76 million | Fiscal year 2014: -$12.17 million | Fiscal year 2013: -$10.78 million | Fiscal year 2012: -$5.07 million | Fiscal year 2011: -$3.43 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: